Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

[
  {
    "op": "replace",
    "path": "/protocolSection/identificationModule/briefTitle",
    "value": "Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Undergoing Surgery"
  },
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/statusVerifiedDate",
    "value": "2013-09"
  },
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/lastUpdateSubmitDate",
    "value": "2013-09-09"
  },
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/lastUpdatePostDateStruct/date",
    "value": "2013-09-10"
  },
  {
    "op": "replace",
    "path": "/protocolSection/sponsorCollaboratorsModule/responsibleParty/type",
    "value": "PRINCIPAL_INVESTIGATOR"
  },
  {
    "op": "add",
    "path": "/protocolSection/sponsorCollaboratorsModule/responsibleParty/investigatorFullName",
    "value": "Lawrence Lum"
  },
  {
    "op": "add",
    "path": "/protocolSection/sponsorCollaboratorsModule/responsibleParty/investigatorTitle",
    "value": "Principal Investigator"
  },
  {
    "op": "add",
    "path": "/protocolSection/sponsorCollaboratorsModule/responsibleParty/investigatorAffiliation",
    "value": "Barbara Ann Karmanos Cancer Institute"
  },
  {
    "op": "replace",
    "path": "/protocolSection/descriptionModule/briefSummary",
    "value": "<p>RATIONALE: Neoadjuvant chemotherapy for women with stage II-III Her negative breast cancer followed by Her2Bi armed activated T cells (ATCs) may significantly improve the pathologic complete response (pCR) rate at the time of surgery.\nArming ex vivo expanded T cells in the laboratory may help the T cells kill more tumor cells when they are put back in the body.\nGiving combination neoadjuvant chemotherapy followed by laboratory-treated T cells before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.</p><p>PURPOSE: This phase II clinical trial is studying how well giving laboratory-treated T cells after neoadjuvant chemotherapy works in treating women with stage II or stage III breast cancer undergoing surgery.</p>"
  },
  {
    "op": "replace",
    "path": "/protocolSection/armsInterventionsModule/interventions/1/otherNames/0",
    "value": "Cytoxan®"
  },
  {
    "op": "replace",
    "path": "/protocolSection/armsInterventionsModule/interventions/2/otherNames/0",
    "value": "Adriamycin®"
  },
  {
    "op": "replace",
    "path": "/protocolSection/armsInterventionsModule/interventions/2/otherNames/1",
    "value": "Rubex®"
  },
  {
    "op": "replace",
    "path": "/protocolSection/armsInterventionsModule/interventions/6/description",
    "value": "As recommended by physician, post immunotherapy."
  }
]